Hank Mansbach

Title: Hank Mansbach: Innovator in Therapeutic Peptide Conjugates

Introduction

Hank Mansbach is a notable inventor based in Herzliya, Israel. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic regimens for treating nonalcoholic steatohepatitis. His innovative work has led to the filing of multiple patents, showcasing his expertise and dedication to advancing medical treatments.

Latest Patents

Hank Mansbach holds 2 patents related to methods of treatment using mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates. His latest patents focus on therapeutic regimens that utilize a polyethylene glycol (PEG) moiety attached to a mutant FGF-21 peptide via a glycosyl moiety. These innovative methods aim to provide effective treatments for nonalcoholic steatohepatitis, highlighting the potential of peptide conjugates in medical applications.

Career Highlights

Mansbach's career is marked by his role at 89Bio, Inc., where he has been instrumental in developing cutting-edge therapies. His work has not only contributed to the company's growth but has also positioned him as a key figure in the biotechnology sector. His dedication to research and innovation continues to drive advancements in therapeutic treatments.

Collaborations

Hank Mansbach collaborates with Chih-Ming Tseng, further enhancing the research and development efforts at 89Bio, Inc. Their partnership exemplifies the importance of teamwork in achieving breakthroughs in biotechnology.

Conclusion

Hank Mansbach's contributions to the field of therapeutic peptide conjugates demonstrate his commitment to innovation and improving patient outcomes. His work continues to inspire advancements in medical treatments, making a significant impact in the biotechnology industry.